for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

GW Pharmaceuticals PLC- ADR

GWPH.O

Latest Trade

218.90USD

Change

0.43(+0.20%)

Volume

225,013

Today's Range

218.22

 - 

218.92

52 Week Range

87.07

 - 

219.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
218.47
Open
218.36
Volume
225,013
3M AVG Volume
21.64
Today's High
218.92
Today's Low
218.22
52 Week High
219.00
52 Week Low
87.07
Shares Out (MIL)
375.20
Market Cap (MIL)
6,888.91
Forward P/E
520.14
Dividend (Yield %)
--

Next Event

GW Pharmaceuticals PLC Court Meeting

Latest Developments

More

GW Pharmaceuticals Receives European Commission Approval For Epidyolex For Treatment Of Seizures Associated With Tuberous Sclerosis Complex

GW Pharmaceuticals Posts Quarterly Loss Per Share $0.08

Jazz Pharma To Acquire GW Pharmaceuticals Plc, Creating An Innovative, High-Growth, Global Biopharma Leader

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About GW Pharmaceuticals PLC- ADR

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company's lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers Sativex (nabiximols), which is indicated for the treatment of spasticity due to multiple sclerosis (MS). The Company is also focused on developing its pharmaceutical product pipelines, which includes Epidiolex for the treatment of Tuberous Sclerosis Complex and RETT Syndrome.

Industry

Biotechnology & Drugs

Contact Info

Sovereign House

Vision Park, Chivers Way

CB24 9BZ

United Kingdom

+44.1223.266800

https://www.gwpharm.com/

Executive Leadership

Geoffrey W. Guy

Executive Chairman of the Board

Justin Gover

Chief Executive Officer, Executive Director

Scott Giacobello

Chief Financial Officer

Christopher John Tovey

Chief Operating Officer

Adam David George

Managing Director - U.K., Company Secretary

Key Stats

2.67 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2019

0.3K

2020

0.5K

2021(E)

0.7K
EPS (USD)

2019

-0.240

2020

-1.800

2021(E)

0.420
Price To Earnings (TTM)
--
Price To Sales (TTM)
13.07
Price To Book (MRQ)
9.22
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
2.06
LT Debt To Equity (MRQ)
1.93
Return on Investment (TTM)
-7.53
Return on Equity (TTM)
-6.38

Latest News

Latest News

Jazz Pharma to buy GW Pharma for $7.2 billion, adding cannabis-based drug to portfolio

Jazz Pharmaceuticals Plc said on Wednesday it had agreed to buy GW Pharmaceuticals plc in a $7.2 billion cash-and-stock deal which will bolster its neuroscience business with the addition of a cannabis-based epilepsy treatment.

Law firms line up as $7.2 bln deal adds cannabis-based Epidiolex to Jazz drug portfolio

More than a half a dozen law firms suited up to advise on Jazz Pharmaceutical's $7.2 billion cash-and-stock acquisition of GW Pharmaceuticals, as pharma and life sciences transactions continue to keep M&A lawyers busy.

Jazz Pharma to buy GW Pharma in $7.2 bln deal

Jazz Pharmaceuticals Plc said on Wednesday it would buy GW Pharmaceuticals plc in a cash-and-stock deal worth $7.2 billion. (Reporting by Ankur Banerjee in Bengaluru; Editing by Shailesh Kuber)

BRIEF-GW Pharmaceuticals Announces Epidyolex® Has Been Reclassified By The Uk Home Office As A Schedule 5 Drug

* GW PHARMACEUTICALS ANNOUNCES THAT EPIDYOLEX® (CANNABIDIOL) HAS BEEN RECLASSIFIED BY THE UK HOME OFFICE AS A SCHEDULE 5 DRUG

GW Pharma cannabis drug set to hit market following DEA nod

U.S.-listed shares of GW Pharmaceuticals rose 8 percent on Thursday as its marijuana-based treatment Epidiolex cleared the last hurdle after the Drug Enforcement Administration labeled the drug as having a low abuse potential.

U.S. approves first marijuana plant-derived drug for epilepsy

The U.S. health regulator approved GW Pharmaceuticals Plc's epilepsy treatment on Monday, making it the first cannabis-based drug to win approval in the country and opening floodgates for more research into the medicinal properties of cannabis.

CORRECTED-(OFFICIAL)-UPDATE 3-U.S. approves first marijuana plant-derived drug for epilepsy

* FDA approves GW's drug to treat two severe forms of epilepsy

GW Pharma wins U.S. approval for marijuana-derived epilepsy drug

An epilepsy treatment from GW Pharmaceuticals Plc on Monday secured an approval from the U.S. Food and Drug Administration, becoming the first cannabis-based drug to be approved in the country.

BRIEF-GW Pharmaceuticals Qtrly Loss Per ADS 312.0 Cents

* GW PHARMACEUTICALS PLC REPORTS FISCAL SECOND QUARTER 2018 FINANCIAL RESULTS AND OPERATIONAL PROGRESS

GW Pharma gets FDA panel nod, first cannabis-based drug nearing approval

An advisory panel to the U.S. Food and Drug Administration on Thursday unanimously voted in favor of approving the first cannabis-derived medicine in the country, a childhood epilepsy treatment developed by GW Pharma.

BRIEF-GW Pharma Announces Unanimous Positive Result Of FDA Advisory Committee Meeting

* GW PHARMACEUTICALS AND U.S. SUBSIDIARY GREENWICH BIOSCIENCES ANNOUNCES THE UNANIMOUS POSITIVE RESULT OF FDA ADVISORY COMMITTEE MEETING FOR FIRST PLANT-BASED PHARMACEUTICAL CANNABIDIOL TREATMENT FOR SEIZURES IN PATIENTS WITH TWO RARE, SEVERE FORMS OF EPILEPSY

BRIEF-GW Pharma Says Presenting CBD-OS Product In Advisory Committee Meeting With FDA On April 19

* GW PHARMACEUTICALS SAYS PRESENTING CBD-OS PRODUCT (EPIDIOLEX) IN ADVISORY COMMITTEE MEETING WITH FDA ON APRIL 19 - SEC FILING Source text: (https://bit.ly/2HK1BW3) Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up